Want to see HK:3692 full AI Analyst Report?
3692 Stock Chart & Stats
HK$39.76
HK$0.26(1.60%)
At close: 4:00 PM EST
HK$39.76
HK$0.26(1.60%)
Day’s Range― - ―
52-Week RangeHK$28.06 - HK$44.22
Previous CloseN/A
Volume4.63M
Average Volume (3M)9.67M
Market Cap
HK$200.48B
Enterprise ValueHK$181.91K
Total Cash (Recent Filing)HK$31.58B
Total Debt (Recent Filing)HK$105.14M
Price to Earnings (P/E)30.7
Beta0.54
Next Earnings
Aug 20, 2026EPS Estimate
0.57Next Dividend Ex-DateN/A
Dividend Yield1.33%
Share Statistics
EPS (TTM)0.93
Shares Outstanding6,064,150,000
10 Day Avg. Volume6,926,281
30 Day Avg. Volume9,666,344
Financial Highlights & Ratios
PEG Ratio1.36
Price to Book (P/B)5.48
Price to Sales (P/S)12.90
P/FCF Ratio31.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$45.72Price Target Upside14.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.99
Revenue Forecast (FY)HK$16.93B
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained, exceptionally high gross and net margins reflect strong pricing power and a branded prescription portfolio. High margins support durable internal funding for R&D, commercialization and margin-backed cash generation, improving long-term earnings quality and reinvestment capacity.
Conservative Balance SheetExtremely low leverage and a large equity base provide financial flexibility and resilience to policy or procurement cycles. Low debt reduces refinancing risk, enabling the company to fund R&D, launches or M&A from internal resources without straining cash flow over the medium term.
Strong Cash GenerationOperating cash well above reported earnings and free cash flow tracking net income indicate high earnings quality and the ability to fund ongoing commercialization, capex and R&D internally. Consistent cash conversion supports strategic optionality and shareholder returns over time.
Bears Say
Top-line VolatilityRevenue trajectory shows meaningful year-to-year swings tied to launches, approvals and procurement cycles. Such top-line volatility complicates long-term planning for R&D investment and commercialization, and increases execution risk for sustaining steady growth over multiple years.
Margin & Cash Conversion VariabilityAlthough margins are high on average, historical dips and weaker cash coverage in some years indicate earnings can fluctuate with product mix, pricing and reimbursement shifts. This variability makes forward earnings and free cash flow less predictable for strategic budgeting.
Historical Leverage SwingsPast increases in leverage show management is willing to alter capital structure cyclically. In stress or growth funding scenarios, re-leveraging could raise refinancing or interest risks, reducing the balance sheet durability that presently appears strong.
Hansoh Pharmaceutical Group Company Limited News
3692 FAQ
What was Hansoh Pharmaceutical Group Company Limited’s price range in the past 12 months?
Hansoh Pharmaceutical Group Company Limited lowest stock price was HK$28.06 and its highest was HK$44.22 in the past 12 months.
What is Hansoh Pharmaceutical Group Company Limited’s market cap?
Hansoh Pharmaceutical Group Company Limited’s market cap is HK$200.48B.
When is Hansoh Pharmaceutical Group Company Limited’s upcoming earnings report date?
Hansoh Pharmaceutical Group Company Limited’s upcoming earnings report date is Aug 20, 2026 which is in 28 days.
How were Hansoh Pharmaceutical Group Company Limited’s earnings last quarter?
Hansoh Pharmaceutical Group Company Limited released its earnings results on Mar 29, 2026. The company reported HK$0.464 earnings per share for the quarter, beating the consensus estimate of HK$0.394 by HK$0.07.
Is Hansoh Pharmaceutical Group Company Limited overvalued?
According to Wall Street analysts Hansoh Pharmaceutical Group Company Limited’s price is currently Undervalued.
Does Hansoh Pharmaceutical Group Company Limited pay dividends?
Hansoh Pharmaceutical Group Company Limited pays a Quarterly dividend of HK$0.2 which represents an annual dividend yield of 1.33%. See more information on Hansoh Pharmaceutical Group Company Limited dividends here
What is Hansoh Pharmaceutical Group Company Limited’s EPS estimate?
Hansoh Pharmaceutical Group Company Limited’s EPS estimate is 0.57.
How many shares outstanding does Hansoh Pharmaceutical Group Company Limited have?
Hansoh Pharmaceutical Group Company Limited has 6,064,150,000 shares outstanding.
What happened to Hansoh Pharmaceutical Group Company Limited’s price movement after its last earnings report?
Hansoh Pharmaceutical Group Company Limited reported an EPS of HK$0.464 in its last earnings report, beating expectations of HK$0.394. Following the earnings report the stock price went down -0.644%.
Which hedge fund is a major shareholder of Hansoh Pharmaceutical Group Company Limited?
Currently, no hedge funds are holding shares in HK:3692
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hansoh Pharmaceutical Group Company Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.01%
12-Months-Change
Fundamentals
Return on Equity
1.33%
Trailing 12-Months
Asset Growth
31.91%
Trailing 12-Months
Company Description
Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
3692 Stock 12 Month Forecast
Average Price Target
HK$45.72
▲(14.98% Upside)
Technical Analysis
HUTCHMED (China)
―
China Medical System Holdings
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
China Resources Pharmaceutical Group Ltd.
―